Table 6.
Dose reductions (Japanese safety population)
|
Dacomitinib n = 40 |
Gefitinib n = 41 |
|
|---|---|---|
| No dose reduction, n (%) | 6 (15.0) | 31 (75.6) |
| Lowest dose on study (dacomitinib: reduction to 30 mg/d; gefitinib: reduction to 250 mg every 2 d), n (%) | 11 (27.5) | 6 (14.6) |
| Lowest dose on study (dacomitinib: reduction to 15 mg/d; gefitinib: >1 dosing change a ), n (%) | 23 (57.5) | 4 (9.8) |
| Any dose reduction, n (%) | 34 (85.0) | 10 (24.4) |
Cutoff date: July 29, 2016.
a
Additional dose reduction(s) for gefitinib followed re‐escalation of dose to 250 mg once daily after dose reduction.